arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Syndax Pharmaceuticals Inc

SNDX
$20.41 ▲ +0.64 (+3.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
47 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Syndax Pharmaceuticals Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8B
Dividend Yield
Revenue Growth 223.6%
Op. Margin -52.7%
ROIC -64.9%
FCF / Share $-0.57
Trailing P/E
Price / Book 43.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$64.86M
↑ +223.6%
Net Income Profit after all expenses
$-42.67M
↑ +49.7%
Operating Margin Operating profit as % of sales
-52.7%
↑ +42.1% 1th
FCF / Share Free cash flow per share
$-0.57
↑ +48.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters